MedMen Reports Loses $277 Million For The Year, $82 Million In The Quarter

MedMen Enterprises Inc.  (CSE: MMEN) (OTCQX: MMNFF) fourth-quarter revenue of $42 million, up 104% year over year, but the net losses were an eye-popping $82.9 million.

The company’s full-year revenue was $130 million, up 227% year over year. The full-year net loss was $277.0 million, with net loss attributable to shareholders of MedMen Enterprises $79.1 million or loss of $0.75 per basic and diluted share. The company spent $42 million in executive compensation for the year. This compares to a net loss of $113.9 million, with net loss attributed to shareholders of MedMen Enterprises $68.3 million or loss of $1.69 per basic and diluted share, for fiscal 2018.

“Fiscal 2019 was a transformative year for MedMen, with over two million completed retail transactions to date and revenues increasing 227% year-over-year,” said Adam Bierman, MedMen co-founder and chief executive officer. “Our success was due, largely in part, to our loyal customer base. Throughout the year, we served over one million customers from all 50 states and more than 100 countries. In California, the largest cannabis market in the world, MedMen surpassed a record $110 million in annualized run-rate retail revenue.”

Mr. Bierman continued, “While industry tailwinds propelled us forward over the past twelve months, changing macroeconomic conditions have led us to refocus our strategy, to reevaluate our assets and to determine where it makes most sense to allocate capital going forward. As we progress into the next fiscal year, our go-forward strategy will therefore focus on three key objectives: optimizing our current retail assets, unlocking the further potential of our factories, and leveraging our omnichannel strategy. As we bring all of our factories online and up to full capacity, and simultaneously optimize our current retail assets across our core geographic markets, we continue on our path toward profitability.”

Gross margins fell to 50% in the fourth quarter compared to 53% in the prior quarter. The company attributed the decline in gross margins “to new store openings, which initially have lower gross margins.” The company reported an Adjusted EBITDA loss of $39.4 million for the fourth quarter, representing a 7% improvement from the previous quarter.

The company wrote in its filing that it could be considered at risk of ongoing concern citing, “The amount of new revenue to be generated from ongoing and planned operationalization of existing licenses to provide sufficient cash flow to fund operations and other committed expenditures.”

Production Costs Flat, Prices Fall

Costs of Production Per Gram were essentially flat $0.70 to $3.30 (2019) versus $0.72 to $3.05 (2018). Prices fell though, Selling Price Per Active Gram $3.26 to $5.61 (2019) versus $5.28 to $6.54 (2018).

California

MedMen seems to have refocused itself on the California market versus a nationwide expansion. The California retail revenue totaled $27.5 million for the quarter. MedMen increased its total California retail license count to 17. Of these 17 retail licenses, 13 are operational as MedMen stores. The company was also recently awarded a commercial retail license in Pasadena, California. MedMen said it expects to have a total of 30 operating retail locations in California by the end of the calendar year 2020.

MedMen added a flagship retail location in Long Beach situated strategically between its Santa Ana and LAX stores. The company also opened a second San Diego retail location in Sorrento Valley. During the quarter, MedMen was also awarded one of six retail licenses available in the City of Pasadena. MedMen continued to expand its Northern California retail footprint announcing plans to open a retail store in the city of Vallejo upon completion of a pending acquisition of a retail and distribution license.

The City Council of West Hollywood passed an ordinance to extend MedMen’s temporary recreational retail license until January 1, 2021, unless otherwise determined. MedMen continues to work with West Hollywood City Council and various community groups on a long-term resolution.

 

Debra Borchardt

Debra BorchardtDebra Borchardt

Debra Borchardt is the CEO, Co-Founder, and Editor-In-Chief of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Masters degree in Business Journalism from New York University.


One comment

  • Avatar
    Himanshu Agrawal

    October 30, 2019 at 2:42 am

    What is the cultivation cost of fresh medicinal cannabis and cbd oil in USA generally.

    What is the average bulk selling price of CBD oil in USA.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 19 hours

$ACRG ⁦@AcreageCannabis⁩ Buys New Jersey’s Compassionate Care For Undisclosed Amount. Co trailed competition but ga…

@GreenMarketRpt – 20 hours

⁦@medmen⁩ $MMNFF $MMEN Faces Reality, Slashes Employees, Scales Back Expansion

Back to Top

You have Successfully Subscribed!